Novel drug combination for tuberculosis to be tested across 50 sitesBMJ 2014; 348 doi: https://doi.org/10.1136/bmj.g3535 (Published 27 May 2014) Cite this as: BMJ 2014;348:g3535
- Sanjeet Bagcchi
A new phase III clinical trial of a novel combination of three drugs for tuberculosis (TB) is set to be launched by the end of the year in 50 sites across Africa, Asia, eastern Europe, and Latin America, the charity TB Alliance has said.1
The STAND (Shortening Treatments by Advancing Novel Drugs) trial will evaluate the drug combination known as PaMZ, which contains two candidate drugs that are not yet licensed for the treatment of tuberculosis, PA-824 (Pa) and moxifloxacin (M), and one existing antituberculosis drug, pyrazinamide (Z).
Study results have shown that PaMZ has the potential to treat patients with drug sensitive and drug …
Log in using your username and password
Log in through your institution
Sign up for a free trial